Wells Fargo’s Taysha Gene Therapies TSHA Stock Holding History

Wells Fargo’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Buy	333,314 +149,980	+82%	+$888K	﹤0.01%	3488
2026 Q1	$820K	Sell	183,334 -121,752	-40%	-$566K	﹤0.01%	3854
2025 Q4	$1.68M	Buy	305,086 +159,988	+110%	+$777K	﹤0.01%	3588
2025 Q3	$474K	Buy	145,098 +37,864	+35%	+$107K	﹤0.01%	4339
2025 Q2	$248K	Sell	107,234 -1,814	-2%	-$3.94K	﹤0.01%	4644
2025 Q1	$152K	Buy	109,048 +5,664	+5%	+$9.47K	﹤0.01%	4866
2024 Q4	$179K	Buy	103,384 +31,457	+44%	+$65.3K	﹤0.01%	4864
2024 Q3	$145K	Buy	71,927 +2,185	+3%	+$4.79K	﹤0.01%	4791
2024 Q2	$156K	Buy	69,742 +62,334	+841%	+$181K	﹤0.01%	4669
2024 Q1	$21.3K	Sell	7,408 -21	-0.3%	-$44	﹤0.01%	5560
2023 Q4	$13.1K	Buy	7,429 +889	+14%	+$1.77K	﹤0.01%	5756
2023 Q3	$20.7K	Sell	6,540 -12,653	-66%	-$23.6K	﹤0.01%	5583
2023 Q2	$12.7K	Buy	19,193 +15,148	+374%	+$11K	﹤0.01%	5849
2023 Q1	$3.23K	Buy	4,045 +2,777	+219%	+$3.59K	﹤0.01%	6147
2022 Q4	$2.87K	Buy	1,268 +318	+33%	+$644	﹤0.01%	5919
2022 Q3	$2K	Buy	950 +787	+483%	+$2.86K	﹤0.01%	6203
2022 Q2	$1K	Sell	163 -1,282	-89%	-$5.09K	﹤0.01%	6615
2022 Q1	$9K	Sell	1,445 -8,014	-85%	-$59.9K	﹤0.01%	6320
2021 Q4	$110K	Buy	+9,459	New	+$143K	﹤0.01%	5580
2021 Q2	–	Sell	-57,412	Closed	-$1.17M	–	7450
2021 Q1	$1.17M	Buy	57,412 +44,971	+361%	+$1.22M	﹤0.01%	4143
2020 Q4	$330K	Buy	+12,441	New	+$268K	﹤0.01%	4813

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wells Fargo's TSHA Position: Q2 2026 in Review

Wells Fargo increased its Taysha Gene Therapies (TSHA) stake by 82% in Q2 2026, buying an estimated $888K and bringing the position to 333,314 shares worth $2.27M. The position accounts for ﹤0.01% of the portfolio, ranked #3488.

Wells Fargo first reported a position in TSHA in Q4 2020 and has held it in 21 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Wells Fargo held 333,314 shares of Taysha Gene Therapies worth $2.27M as of Q2 2026.
Wells Fargo bought 149,980 Taysha Gene Therapies shares in Q2 2026, an estimated $888K.
Taysha Gene Therapies made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3488 holding.
Wells Fargo first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 21 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.